The Power of PoP

POP BIO uses two patented porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in oncology and infectious disease

1.) The Spontaneous Nanoliposome Antigen Particleization (SNAP) platform enables the rapid development of highly immunogenic vaccines

2.) Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors expose to specific laser light.

Learn more about our technologies

Latest News

November 30, 2022

POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
November 30, 2022

POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
February 4, 2022

POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.